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Abstract  
Background: There is some evidence for the efficacy of cognitive behavior therapy (CBT) for 
body dysmorphic disorder (BDD) after 1-6 months but none in the long-term. Aims: The aim 
of this study was to follow-up the participants in a randomized controlled trial of CBT versus 
anxiety management to determine whether or not the treatment gains were maintained over 
time. Method: Thirty of the original 39 participants who had CBT were followed up over 1-4 
years and assessed using a number of clinician and self-report measures, which included the 
primary outcome measure of the Yale-Brown Obsessive Compulsive Scale modified for 
BDD. Results: Outcome scores generally maintained over time from end of treatment to 
long-term follow-up. There was a slight deterioration from n=20 (51.3%) to n=18 (46.2%) 
who met improvement criteria at long-term follow-up. Eleven (28.2%) were in full remission 
and 22 (56.4%) were in partial remission. Conclusions: The gains made were generally 
maintained at long-term follow-up. However, there were a significant number of participants 
who maintained chronic symptoms after treatment and may need a longer-term or more 
complex intervention and active medication management.   
 
 
Keywords: body dysmorphic disorder; follow-up; long-term; cognitive behavior therapy; 
treatment   
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Long term outcome of Cognitive Behavior Therapy for Body Dysmorphic Disorder: A 
naturalistic case series of 1 to 4 years   
 
Body dysmorphic disorder (BDD) consists of a preoccupation with a perceived defect 
or ugliness, most commonly around the face. The ‘flaw(s)’ is not noticeable to others, or 
appears only slight, yet causes enormous shame, depression, and a poor quality of life 
(Phillips, 2000). BDD is reported as a chronic and unremitting condition (Phillips, Pagano, 
Menard, & Stout, 2006) with  sufferers experiencing high rates of being housebound, 
hospitalization, suicide attempts and completed suicide (Phillips, Coles, et al., 2005; Phillips 
& Diaz, 1997; Phillips, Menard, & Fay, 2006; Veale, Boocock, et al., 1996).  It is therefore 
particularly important to develop and evaluate interventions for such a disabling condition. 
The UK National Institute of Health and Clinical Excellence (NICE) guidelines on OCD and 
BDD recommended the use of Cognitive Behavior Therapy (CBT) that is specific for BDD, 
and Selective Serotonin Reuptake Inhibitors (National Collaborating Centre for Mental 
Health, 2006). However, the evidence base for this recommendation is relatively poor and 
little is known about long-term outcomes of treatment. To date, there are 4 RCTs that have 
evaluated CBT for BDD against a wait list. These are all small studies that have 
demonstrated greater efficacy of CBT compared to a wait-list over 12-22 sessions (Rabiei, 
Mulkens, Kalantari, Molavi, & Bahrami, 2012; Rosen, Reiter, & Orosan, 1995; Veale, 
Gournay, et al., 1996; Wilhelm et al., 2014). These studies reported follow-up outcomes 
between 1 to 6 months where participants have generally maintained their gains. McKay 
(1999) reported on a 2 year follow-up of 10 participants after they received behavior therapy 
for 6 weeks and were randomly assigned to either a maintenance program or a control group 
for 6 months. The author found that a maintenance program was superior to no maintenance 
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at 2-year follow-up. No RCTs have examined whether a selective serotonin reuptake inhibitor 
(SSRI) can enhance outcome of CBT for BDD either in the short or long-term.   
There are 4 long-term naturalistic outcome studies of people with BDD with 12-
month outcomes (Fontenelle et al., 2006; Phillips, Grant, Siniscalchi, Stout, & Price, 2005; 
Phillips, Pagano, et al., 2006). In these studies, full remission was defined as minimal or no 
BDD symptoms, and partial remission as meeting less than full DSM-IV criteria for at least 8 
consecutive weeks. Phillips, Grant, et al. (2005) retrospectively assessed that at 1 year 
follow- up, 24.7% of 95 participants had achieved full remission, while another 33.1% had 
experienced partial remission at the 6-month and/or 12-month follow-up. After 4 years, 
58.2% of subjects had reached full remission, and another 25.6% had experienced partial 
remission. Of those subjects who attained partial or full remission, 28.6% subsequently 
relapsed. Although all patients had received SSRI medication, only 21.7% had received CBT.  
Phillips, Pagano, et al. (2006) conducted a prospective follow-up of 183 participants 
in which 9% achieved a full remission and 21% partial remission at 1-year follow-up. There 
was an overall average probability of relapse of .15 in the study. Although most patients had 
received psychotropic medication, only 16% was considered optimal and only 21.9% had 
received CBT, in which it was difficult to judge the quality.  
Phillips, Menard, Quinn, Didie, and Stout (2013) conducted a prospective 4-year 
follow-up of 166 adults and adolescents with BDD. After 4 years, 20% had achieved full 
remission from BDD and a further 35% partial remission. Eighty-eight percent of subjects 
received mental health treatment during the follow-up period although only 10.2% had an 
optimal length of course of CBT and 34.3% received a SSRI that was considered optimal. 
Among partially or fully remitted subjects, the cumulative probability was 0.42 for 
subsequent full relapse and 0.63 for subsequent full or partial relapse. A lower likelihood of 
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full or partial remission was predicted by more severe BDD symptoms at intake, longer 
lifetime duration of BDD, and being an adult.  
Lastly Bjornsson et al. (2013) conducted a naturalistic study in an anxiety disorders 
clinic. They measured recovery from BDD in 17 participants with current BDD and 22 with a 
lifetime history of BDD for up to 8 years, and found a recovery probability of 0.76. The 
probability of recurrence of BDD, once remitted, was low at 0.14. However, it is not known 
how representative this sample was.  
The present study is a follow-up report of Veale, Anson, et al. (2014), who conducted 
a RCT to determine if CBT had greater efficacy than anxiety management (AM) in BDD. 
Forty-six participants were randomly allocated to either CBT or AM. The participants were 
fairly typical of outpatients with severe BDD, with a mean BDD-Yale Brown Obsessive 
Compulsive Score of 35.5 at baseline, and 83% desiring at least one cosmetic or 
dermatological procedure.  These individuals are difficult to engage, and both the expectancy 
of change and credibility of CBT or AM were rated as very low. Fifty-four percent were 
classified as having a delusional BDD. Sixty one percent had had a previous trial of a 
selective serotonin reuptake inhibitor (SSRI) and 45% of participants were stabilized on a 
SSRI at entry. Thirty seven percent had had previous trial of CBT.  
The primary end-point was at 12 weeks and the CBT group, unlike the AM group, 
had 4 further weekly sessions that were analysed for their added value. Both groups then 
completed measures at their 1-month follow-up.  At 12 weeks, CBT was found to be 
significantly superior to AM on the BDD-YBOCS (β = -7.19, S.E. (β) = 2.61, p < .01, C.I. = -
12.31, -2.07, d= 0.99) and on the secondary outcome measures. The conclusion was that CBT 
was a more effective intervention than AM for individuals with BDD even for those with 
delusional beliefs or depression at 12 weeks. Participants who were originally randomized to 
receive AM and still had BDD were then offered up to 16 sessions of CBT. The current study 
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was exploratory and aimed to follow-up all participants who had CBT from the original 
sample, either as a first or second treatment, to see how their outcomes had changed over 
time since offered CBT. The difference to previous follow-up studies is that all participants 
had received CBT and about 45% had received a SSRI. We hypothesized that non-responders 
in the long term were more likely to have higher levels of depression and delusional beliefs at 
assessment. Although a previous follow-up study in BDD found only a trend for depression 
predicting lower remission (Phillips et al., 2013),  other follow-up studies in anxiety disorders 
have found depression to be associated with a worse outcome, for example in CBT for post 
traumatic stress disorder (Johnson, 1987), obsessive compulsive disorder (Knopp, Knowles, 
Bee, Lovell, & Bower, 2013), social phobia (Green, 2009) and generalized anxiety disorder 
(Foa & Goldstein, 1978). We also hypothesized that participants recruited from a secondary 
care were more likely to be non-responders. This is because individuals in secondary and 
tertiary care are under the care of psychiatric team and have more complex needs – for 
example they tend to have greater comorbidity and social problems than those recruited those 
from primary care and the Improving Access to Psychological Therapies (IAPT) service, and 
who are not under any psychiatric care (Gyani, Shafran, Layard, & Clark, 2013). This is part 
of “stepped care” system in which the care of a patient is provided according to their need or 
they are stepped up to a higher level of care if they fail at a lower level.    
Method 
Participants 
Participants were recruited from the original sample who all had a diagnosis of BDD 
according to DSM-IV (American Psychiatric Association, 1994) as their main problem, a 
total score of 24 or more on the Yale Brown Obsessive Compulsive Scale modified for BDD 
(BDD-YBOCS) (Phillips et al., 1997), were 18 years old or over, and were either not on 
medication or had been on a stable dose for 12 weeks. Recruitment took place using one of 
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three methods: (a) sending letters to the participant’s home address; (b) telephoning the 
participant or (c); sending them an email. Recruitment took place between January 2014 and 
July 2014. 
Design 
The study was a longitudinal follow-up for a case series of between 1 to 4 years 
(20.23 months on average) of a sample originally recruited to a single blind randomized 
controlled trial. For detailed descriptions of the original study design, participants, materials 
and procedure please refer to the original paper (Veale, Anson, et al., 2014). 
Materials 
A range of clinician rated measures were conducted with a trained research worker. 
The Yale Brown Obsessive Compulsive scale modified for BDD (BDD-YBOCS) (Phillips et 
al., 1997) was the primary outcome measure. The scale consists of 12 questions that are rated 
from 0 to 4. Total scores are summed to give a range from 0 to 48. Higher scores indicate 
higher BDD symptomatology. Cronbach’s alpha in our sample was .96. Response or “much 
improvement” to treatment was defined as 30% or greater decrease in the total BDD-
YBOCS, which best corresponded to “much” or “very much improved” on the Clinical 
Global Impression (CGI) scale (Phillips, Hart, & Menard, 2014). In addition, criterion “a” of 
at least 2 standard deviations from the sample mean was used to calculate reliable and 
clinically significant change of participants’ scores over time, as there are no normative data 
for the BDD-YBOCS in a “general” population range to determine criterion b or c (Jacobson 
& Truax, 1991).This equated to a decrease of 8 points on the BDD-YBOCS.  The following 
assumptions were used for the calculation. The pre-treatment mean and standard deviation of 
the BDD-YBOCS for BDD sample was 34.77 (6.78). The Standard Error of measurements 
for the BDD-YBOCS was 3.03. The standard error of difference between the two test scores 
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was 4.29. The Reliable Change Index was therefore 4.29 x 1.96 = 8.41 (or 8 rounded to a 
whole number).  
The Brown Assessment of Beliefs Scale (BABS) (Eisen et al., 1998) is a 7-item 
clinician rated scale, rated by a blind assessor, measuring the strength of conviction in a 
belief (e.g. “I am as ugly as the Elephant man”). Each item score ranges from 0 (least 
conviction) to 4 (most conviction). Items are summed to give a total score ranging from 0 to 
24; (the final item does not contribute to the total score). Higher scores represent increasing 
delusionality. The Cronbach’s alpha in our sample was .92. 
The Montgomery Asberg Depression Rating scale (MADRS) (Montgomery & 
Asberg, 1979) is a 10-item clinician scale rated by a blind assessor to measure symptoms of 
depression. Each item is rated on a 7-point Likert scale from 0 (indicating no difficulties) to 6 
(indicating high or abnormal levels of difficulties). The item scores are summed to give a 
total scale score with a range from 0 to 60, with higher scores reflecting greater 
symptomatology. A classification of depression was made on all those with a MADRS total 
score ≥25. A total score ≥25 and <31 is regarded as moderate, and ≥31 as severe symptoms. 
The scale had good inter-rater reliability, which correlated before treatment at .89, and after 
treatment at .95. The Cronbach’s alpha in our sample was.90.  
A series of self-report measures were also administered as detailed below. The 
Appearance Anxiety Inventory (AAI) (Veale, Eshkevari, et al., 2014) is a 10-item self-report 
questionnaire for measuring frequency of avoidance and threat-monitoring (e.g. checking) 
that are characteristic of a response to a distorted body image. Each item is scored from 0 
(“not at all”) to 4 (“all the time”). A total score is summed to range between 0 and 40 with 
higher scores reflecting greater frequency of the responses. Cronbach’s alpha in our sample 
was .94.  
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The Patient Health Questionnaire (PHQ-9) (Kroenke & Spitzer, 2002) is a 9-item self-
report measure of depression. Items are scored from 0 (“not at all”) to 3 (“nearly every day”). 
The total score ranges from 0 to 27 with higher scores reflecting greater symptomatology of 
depression. Cronbach’s alpha in our sample was .94.  
The Generalized Anxiety Disorder (GAD-7) (Spitzer, Kroenke, Williams, & Löwe, 
2006) is a 7-item self-report measure for symptoms of generalized anxiety. Each item is rated 
from 0 (“not at all”) to 3 (“nearly every day”). The total score ranges from 0 to 21, with 
higher scores reflecting greater symptomatology. Cronbach’s alpha in our sample was .93.  
The Body Image Quality of Life Inventory (BIQLI) (Cash & Fleming, 2002) is a 19-
item self-report scale that measures the impact of body image concerns on a broad range of 
life domains (e.g. sense of self, social functioning, sexuality, emotional well-being, exercise, 
grooming). The BIQLI is scored as an average numeric score of all the items from -3 (“very 
negative effect”) to + 3 (“very positive effect”). Cronbach’s alpha in our sample was .98.  
Procedure 
After agreeing to take part in the follow-up study and signing an informed consent 
form participants were either (a) sent self-report measures via post to complete and send back 
in a self-addressed stamped envelope, or (b) sent online links to complete each of the self-
report measures on a survey website. The procedure they followed was determined by their 
own preference and self-report measures were completed within participants’ own time-
frame. Following the completion of self-report measures, participants scheduled an 
appointment with the research assistant in which to complete clinician measures and the 
semi-structured interview. Participants could either choose to have an appointment face to 
face in a therapy room at our service, or to complete the interview over the telephone.  
Statistical Analysis 
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The analysis of long-term efficacy of CBT was “intention-to-treat” analyses. 
Therefore, data were analysed from all those who completed baseline measures regardless of 
whether or not they completed the long-term follow-up measures. This was done to control 
for attrition bias. Inserting an average score for questionnaires was used where only one item 
of data was missing. Kolmonogorov-Smirnov, skew and kurtosis tests indicated that outcome 
data were non-parametric and therefore statistical tests run were non-parametric where 
necessary. Last Observation Carried Forward (LOCF) was used where participants had 
dropped out of completing the long-term follow-up stage to the study (non-completers) as 
alternatives such as Multiple Imputation requires parametric data. Descriptive demographic 
statistics for the sample were calculated and compared to those who did not complete the 
long-term follow-up. Wilcoxon signed rank tests were used to determine the change in 
participants’ outcome scores across each of the data collection periods; baseline, week 16 
(treatment end) and long-term follow-up. Scores for completers were also compared to scores 
carried forward for non-completers at long-term follow-up. Percentages and frequencies of 
the following were calculated and where possible compared across time using Exact 
McNemar tests: 
(1) Those who had a 30% decrease in their BDD-YBOCS scores, which was considered 
“very much improved” on the basis that it is significantly correlated with response of BDD 
symptoms measured using the Clinical Global Impressions scale (CGI) (Phillips et al., 1997). 
(2) Those with reliable and clinically significant change in BDD-YBOCS scores, which was 
an 8-point decrease on the BDD-YBOCS. 
(3) Those with “continuous BDD”, which was defined here as having a total BDD-YBOCS 
score of 24 or more across all of the data collection points. 
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(4) Those who achieved “partial remission”, which was defined here as starting the trial with 
a BDD-YBOCS score of 24 or above and then reached a score below 24 but above 12 at a 
subsequent measurement. 
(5) Those who achieved “full remission”, which was defined here as reaching a score of less 
than 12 on the BDD-YBOCS at post-treatment or follow-up. 
(6) Those who relapsed, which was defined here as going back to a BDD-YBOCS score of 24 
or above after having reached partial or full remission.  
Comparisons were then made between participants at baseline who did and did not achieve a 
30% improvement on their BDD-YBOCS score at follow-up for depression, delusionality 
and setting.  
Results 
Figure 1 is a CONSORT flowchart of the numbers of participants that were recruited, 
and from which follow-up data were collected and analysed. In total, 39 (84.8%) of the 
original sample received CBT. Of those, 30 (76.9%) agreed to take part in the long-term 
follow-up. This total was made up of 14 (66.7%) from the original CBT group and 16/25 
(64.0%) from those who crossed over into receiving CBT after anxiety management.  
For 9 (23.1%) participants, LOCF was used for all outcome measures, and for one 
participant this was used for clinician measures only. The most common reasons for not 
taking part in the follow-up were in order of prevalence (a) because participants were 
unreachable (n = 6, 66.7%) and (b) because participants did not wish to be involved (n = 3, 
33.3%). Of the 10 participants to receive CBT who did not complete long-term follow-up 
measures, 5 were also those who dropped-out of their original treatment early. Thirteen 
(33.3%) participants were followed up between 1-2 years after finishing therapy, 12 (30.8%) 
were followed up between 2 and 3 years after, 4 (10.3%) were followed up between 3 and 4 
years after therapy and 1 (2.5%) participant had finished therapy 4 years ago.  
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Demographic Findings 
Demographic characteristics of the sample collected at baseline are presented in Table 
1. The 29 participants who completed all measures for the long-term follow-up did not 
significantly differ from the 10 who did not complete follow-up measures in terms of any 
characteristics shown in Table 1.  
Appearance Concerns 
On average, participants had chronic problems and had been concerned with their   
appearance for a mean of 13.96 years (see Table 1). The most common features of concern 
were in order of prevalence: skin (n = 6, 15.4%); the face in general (n = 5, 12.8%); the nose 
(n = 5, 12.8%); body hair (n = 3, 7.7%); and legs (n = 2, 5.5%). All other concerns (n = 18, 
46.2%) were with the bottom, chin or jaw, eyes, facial hair, facial skin, hairline, lips, 
muscles, penis, stomach, teeth, thighs or thorax. Of all participants, 31 (79.5%) reported 
having multiple concerns. Thirty (76.9%) desired some form of cosmetic surgery, of whom 7 
(23.3%) wanted surgery for their main feature of concern. Five participants (12.8%) had 
undergone a cosmetic procedure in the past. 
Self-Reported Changes over Time from Semi-structured Interviews 
At long-term follow-up, 4 participants reported that they were now not only 
concerned with the physical feature of appearance that they had originally sought treatment 
for, but that they were now excessively preoccupied with an additional feature (2 relating to 
the stomach, 1 to aging and 1 undisclosed). Six participants (15.4%) who had been in a 
relationship when receiving CBT were now single, and 3 participants (7.7%) who had been 
single at the time were now in a relationship. Since finishing treatment, 17 participants 
(43.6%) reported an occupational change. Seven (17.9%) had begun working, 3 (7.7%) had 
stopped working, and 1 (2.6%) had reduced their hours at work. 
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 At the long-term follow-up, 12 (30.8%) participants were taking SSRI medication. Of 
these, 1 had started taking medication, 4 had changed from one SSRI to another, 3 had 
increased the dosage of their SSRI, 1 had decreased the dosage of their SSRI, 2 had changed 
their SSRI and decreased the dosage, 1 had stayed on the same SSRI and dose and 1 had 
stopped taking medication altogether. No other change in psychotropic medication was 
reported.   
Ten participants (25.6%) reported having had further psychological treatment after 
finishing their CBT. Of these, 2 had had another course of CBT, 3 had further CBT from a 
private therapist, and 4 were having a different form of therapy (these included counselling, 
group therapy, occupational therapy, and humanistic therapy). The remaining participant had 
started psychodynamic therapy for borderline personality disorder. Seventeen participants 
(43.6%) were seeking further treatment at the point of long-term follow-up, of whom 3 
(17.6%) had already had further treatment since completing treatment.  
Change over Time according to Standardized Outcome Measures  
Table 2 shows the means and standard deviations, as well as Wilcoxon’s rank 
comparisons for outcome measure scores over time. From pre-treatment to the end of 
treatment, as well as long-term follow-up, body image quality of life significantly increased 
and symptomatology on all other measures significantly decreased. No significant differences 
were observed between the end of treatment and follow-up stages, besides BIQLI scores 
slightly decreasing between week 16 and the long-term follow-up.      
Previous CBT or subsequent treatment 
There was no significant difference in scores on the BDD-YBOCS at baseline, week 
16 or at long-term follow-up between those who had received previous CBT (n=11) and 
those who had not (n= 28) (Table 3).  There was also no significant difference in scores on 
the BDD-YBOCS at baseline, week 16 or at long-term follow-up between those who 
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received psychotherapy or CBT at the end of the trial (n=10) and those who had not (n= 29). 
There were also no significant differences between those who had received a SSRI or 
increase in dose (n=12) compared to those who had not (n=27) (Table 3).    
 “Much Improvement”, Reliable Clinical Change, Remission and Relapse 
Table 4 shows how many participants made much improvement (a 30% decrease in 
BDD-YBOCS scores over time), reliable clinical change, remission, or relapse over time.  
There was a slight deterioration from n=20 (51.3%) to n=18 (46.2%) who met 30% 
improvement criteria for remission. Eleven (28.2%) were in full remission at long-term 
follow-up and 22 (56.4%) were in partial remission (or 84.6% combined in either full or 
partial remission). Relapse probabilities for the participants who had a score of 24 or more on 
the BDD-YBOCS at baseline and then reached full or partial remission are also shown in 
Table 4. Relapse was examined by combining those who had reached either full or partial 
remission. Across follow-up the probability of relapse remained relatively low at n = 4 
(13.3%). Exact McNemar comparisons of frequencies over time indicate that no significant 
differences in patterns of change occurred over the post-treatment follow-up periods alone 
(week 16 to long-term follow-up) for any of the measures. 
             We compared participants on baseline measures for setting recruited, depression 
(MADRS and PHQ9), delusionality (BABS) between those whose BDD-YBOCS scores 
improved by 30% or more at long-term follow-up and those whose scores had not (table 5). 
The findings show that those who did not reach 30% improvement were more likely to have 
been referred to the treatment from a secondary or tertiary care setting, and scored 
significantly higher on the MADRS depression rating scale at baseline (but just failed to 
reached significance on the PHQ9). There was no difference in delusionality on the BABS 
between the groups.  
Duration of follow-up  
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The average duration of time between finishing treatment and completing the current 
long-term follow-up measures was 26.30 months (excluding those lost to follow-up). In a 
multiple regression analysis of the participants who were followed up in the long term, 
duration of follow-up did not predict the difference in baseline and long term BDD-YBOCS 
scores (B = -.071, S.E. B = .246, β = -.052, P = .776) (Supplementary Table 6).  
Discussion 
This is the first study to examine a naturalistic outcome of CBT for BDD of a cohort 
of participants (n=39) in the long-term after 1-4 years. Mean observer rated and self-report 
ratings decreased over time from baseline to long-term follow-up and were maintained from 
16-week follow-up. The categorical data and pattern of change showed participants who 
made significant gains after 16 weeks of CBT generally maintained it. However, about 50% 
made only limited gains with CBT, and continued to have a chronic condition. The only 
differences between those who had a 30% improvement at long-term follow-up and those 
who did not is that the latter were more depressed and were likely to have been recruited 
from a secondary care setting. The finding that symptoms of depression may be a predictor of 
treatment outcome contrasts with Phillips et al. (2013) who did not find major depressive 
disorder to be a predictor of course, or to be significantly associated with rates of remission 
or relapse. However, their finding was based on the categorical dimension of a diagnosis of 
major depressive disorder, whereas our analysis was based on a continuous variable on an 
observer rating scale. It may be that depression may affect the motivation to engage in CBT 
or in relapse prevention. Of note however, is that delusionality does not predict outcome, and 
therefore should not determine suitability for CBT. This is in keeping with Phillips et al. 
(2013) who did not find it a predictor of outcome.  
Further breakdown revealed that 28% of participants were in full remission at follow-
up and that 56% were in partial remission. It is difficult to compare our findings to other 
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naturalistic follow-ups – the rates of full remission in our study are similar compared to 
previous studies who reported 9-25% at 1-2 years and higher than the rate of partial remission 
reported as 21-33% (Fontenelle et al., 2006; Phillips, Grant, et al., 2005; Phillips et al., 2013; 
Phillips, Pagano, et al., 2006). However, Phillips, Grant, et al. (2005) reported that at 4 years, 
58.2% of subjects had now reached full remission, and another 25.6% had experienced partial 
remission. However, there are significant variations in the design between the studies, the 
length of follow-up, the number of participants, and the numbers who received optimal CBT 
or SSRI management.    
The main limitations of the study are the lack of a comparison condition and 
retrospective design. Thus we cannot be sure that maintenance of symptoms was due to CBT. 
Some also had additional treatments during the follow-up. Most participants probably had 
sub-optimal treatment of 16 sessions of CBT and that 24 or more sessions are more likely to 
be required for optimal treatment. It is also possible that a matched number of Anxiety 
Management sessions would benefit some participants. There was also no specific modules 
for treatment of depression which may require additional sessions (Wilhelm et al., 2014). In 
addition there was no active medication management after the trial, for example maximizing 
the dose of a SSRI for 1 to 2 years after treatment. However, the aim of the original study 
was to determine if CBT was more effective than anxiety management after 12 weeks, and in 
our service patients are normally discharged after treatment to their family doctor or 
community mental health team. Another limitation is that the overall numbers followed up 
were relatively small, and we were unable to recruit all the participants from the RCT for the 
follow-up. This meant that we had to estimate the follow-up mean using LOCF and this may 
bias the data towards a better outcome. Small numbers also meant that we might have a Type 
2 error when exploring sub-analyses (for example those who received further therapy after 
the trial against those who did not). We did not use the Psychiatric Status Rating Scale or the 
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-itudinal Interval Follow-Up Evaluation (LIFE), a semi-structured interview and rating 
system that assesses the longitudinal course of mental disorders (Keller, Lavori, Friedman, & 
Nielsen, 1987), as an additional criterion for determining the rates of remission or relapse. 
Instead we used cut-offs on the BDD-YBOCS, so we cannot make adequate comparisons of 
remission rates with previous naturalistic follow-up studies. We also did not measure 
frequency or type of personality disorder to determine if they moderated outcome. We 
identified that severity of depression differentiated a group who made improvements 
compared to those who did not. However, we did not conduct a formal statistical test for 
moderation, as the numbers are relatively small.  
For the half who made partial remission, a future research question is whether their 
outcomes can be optimized further with either a longer out-patient or residential unit 
treatment with modules such as behavioral activation for depression (Dimidjian et al., 2006) 
combined with a maximum tolerated dose of SSRI medication. The long-term outcomes 
might also benefit from a maintenance program and closer follow-up in the first 6 months 
(McKay, 1999). Further research is required to determine whether their outcomes can also be 
improved by adding modules such as compassion focussed therapy for body shame (Veale & 
Gilbert, 2014). BDD may be a condition that requires greater investment in both the 
treatment and maintenance compared to other common emotional disorders.   
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Figure 1 Flow diagram of study participants 
 
 
 
 
Table 1.  
Demographic and clinical characteristics of participants at baseline.  
 
Measure  Total group at baseline 
Completers at 
baseline 
Non-completers at 
baseline Comparison 
N  39 29 10 - 
      
Age in years, mean (SD)   32.23 (9.35) 31.28 (8.54) 35.00 (11.42) U = 120.50, Z = -.789, p = .437, d = 0.25 
      
Sex, n (%) Male 16 (41.0) 13 (44.8) 3 (30.0) Fisher’s exact test p = .480 
Female 23 (59.0) 16 (55.2) 7 (70.0) 
      
Marital Status, n (%)  
       
Single 25 (64.1) 18 (62.1) 7 (70.0) 
Fisher’s exact test p = 1.00 Married or Cohabiting 12 (30.8) 2 (6.9) 3 (30.0) 
Separated or Divorced 2 (5.1) 9 (31.0) 0 (0) 
      
Long-term Relationship, n 
(%) 
Yes 16 (41.0) 11 (37.0) 5 (50.0) 
Fisher’s exact test p = .711 
No 23 (59.0) 18 (62.1) 5 (50.0) 
      
Ethnicity, n (%)  White 30 (76.9) 22 (75.9) 8 (80.0) 
Fisher’s exact test p = 1.00 
 Black 3 (7.7) 2 (6.9) 1 (10.0) 
 Mixed Black and White 2 (5.1) 2 (6.9) 0 (0) 
 Other 4 (10.3) 3 (10.3) 1 (10.0) 
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Employment, n (%)  Unemployed 10 (25.6) 6 (20.7) 4 (40.0) 
Fisher’s exact test p = .803 
 Long-term Sick Leave 2 (5.1) 2 (6.9) 0 (0) 
 Employed or Self-Employed 21 (53.8) 16 (55.2) 5 (50.0) 
 Student (full time) 4 (10.3) 3 (10.3) 1 (10.0) 
 Homemaker 2 (5.1) 2 (6.9) 0 (0) 
      
Current SSRI, n (%) Yes 16 (41.0) 9 (31.0) 7 (70.0) 
Fisher’s exact test p = .062 
 No 23 (59.0) 20 (69.0) 3 (30.0) 
      
Previous CBT, n (%) Yes 11(28.2) 6 (20.7) 5 (50.0) 
Fisher’s exact test p = .109 
 No 28 (71.8) 23 (79.3) 5 (50.0) 
      
Referral, n (%)     Local Primary Care 31 (79.5) 22 (75.9) 9 (90.0) 
Fisher’s exact test p = .653 
 Secondary Care 8 (20.5) 7 (24.1) 1 (10.0) 
      
Duration of problem in 
years, mean (SD)  13.96 (9.30) 13.71 (8.74) 14.70 (11.26) U = 143.50, Z = -.048, p = .962, d = 0.02 
      
Comorbid DSM-IV 
diagnosis, n (%) Yes 23 (59.0) 19 (65.5) 4 (40.0) 
Fisher’s exact test p = .264 
 Delusional BDD 23 (59.0) 15 (51.7) 8 (80.0) 
 Depression 17 (43.6) 14 3 
 Social Phobia 5 (12.8) 3 2 
 Eating Disorder 3 (7.7) 1 2 
 OCD 1 (2.6) 1 0 
 GAD 2 (5.1) 2 0 
 Panic Disorder 1 (2.6) 2 0 
 Alcoholism 2 (5.1) 1 0 
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Table 2.  
Comparisons of standardized outcome measure scores over time (using all 39 participants with LOCF). 
 
Measure 
Point of measurement    
Baseline 
Mean (SD) 
Week 16  
Mean (SD) 
Long-term follow-up 
Mean (SD) 
Baseline – Week 16 
Z, p, d 
Baseline – Long-term follow-up 
Z, p, d 
Week 16 - Long-term follow-up 
Z, p, d 
BDD-YBOCS 34.77 (6.78) 22.14 (12.20) 21.79 (14.55) Z = -5.21, p < .001, d = 3.03 Z = -4.89, p < .001, d = 2.52 Z = -.049, p =.964, d = 0.02 
MADRS 27.84 (11.52) 19.26 (12.92) 18.08 (14.39) Z = -3.61, p < .001, d = 1.42 Z = -3.84, p < .001, d = 1.56 Z = -.430, p = .674, d = 0.14 
BABS 18.33 (5.22) 11.49 (7.39) 11.59 (7.63) Z = -4.76, p < .001, d = 2.35 Z = -4.30, p < .001, d = 1.90 Z = -.429, p = .675, d = 0.14 
AAI 24.64 (7.88) 14.46 (9.23) 11.87 (18.82) Z = -4.93, p < .001, d = 2.57 Z = -4.70, p < .001, d = 2.29 Z = -.824, p = .417, d = 0.27 
PHQ-9 13.69 (6.47) 9.21 (7.33) 9.41 (7.63) Z = -3.26, p = .001, d = 1.22 Z = -3.04, p = .002, d = 1.11 Z = -.123, p = .906, d = 0.04 
GAD-7 12.15 (6.05) 7.59 (6.05) 7.87 (6.00) Z = -3.57, p < .001, d = 1.39 Z = -3.74, p < .001, d = 1.50 Z = -.049, p = .965, d = 0.02 
BIQLI -1.96 (0.64) -1.31 (1.12) -2.36 (9.32) Z = -2.60, p = .009, d = 0.92 Z = -3.53, p < .001, d = 1.37 Z = -2.41, p = .015, d = 0.84 
 
 
 
 
Running head: LONG-TERM OUTCOME OF CBT FOR BDD 29 
Table 3.  
BDD-YBOCs scores in those with or without previous CBT, additional psychotherapy or medication after end of trial  
 
Time  Baseline Week 16 Long-term follow-up 
Subgroup N (%) Mean (SD) Statistics Mean (SD) Statistics Mean (SD) Statistics 
Previous CBT 11 (28.2) 35.36 (5.99) U =148.50 24.82 (11.80) U = 127.50, 24.00 (16.99) U = 138.00, 
  
Z = -.172, 
 
Z = -.828, 
 
Z = -.500, 
No previous CBT 28 (71.8) 34.54 (7.15) p = .866 21.11 (12.40) p = .414 20.93 (13.73) p = .633 
  d = 0.06  d = 0.27  d = 0.16 
Additional psychotherapy post-RCT 10 (25.6) 34.60 (4.14) U = 100.50 25.90 (8.29) U = 127.00, 20.90 (13.04) U = 140.00, 
  Z = .253  Z = 1.47,  Z = -.459, 
No additional psychotherapy post-
RCT 
29 (74.4) 33.68 (7.41) p = .804, 19.11 (11.17) p = .151 22.63 (13.53) p = .668 
  d = 0.08  d = 0.49  d = 0.15 
        
Medication change post-RCT 12 (30.8) 36.33 (5.19) U = 135.00 24.67 (10.21) U = 129.50 25.67 (13.56) U = 75.50 
   Z = -.823  Z = -.990  Z = -1.175 
No Medication change post-RCT 27 (69.2) 34.07 (7.35) p = .411 21.04 (13.00) p = .322 19.47 (12.63) p = .240 
   d = 0.34  d = 0.31  d = 0.49 
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Table 4.  
Within group frequency comparisons of change over time for participants.  
 
Measure 
Change over time     
Week 16   
n (%) 
Long-term follow-up 
n (%) 
 Baseline to  
week 16 
Baseline to long  
term follow-up  
Week 16 to long  
term follow-up 
Improved (> 30% 
decrease in BDD-
YBOCS)  
Not improved(< 30% 
decrease in BDD-
YBOCS)  
20 (51.3) 
 
19 (48.7) 
18 (46.2) 
 
21 (53.8) 
Maintained improvement - - 14 (35.9) 
Remained no improvement - - 15 (38.5) 
Became 30% improved or more - - 4 (10.3) 
Became < 30% improved - - 6 (15.4) 
McNemar comparison p - - .754 
       
 
Reliable Clinical Change 
(RCC) 
Not meeting RCC 
 
25 (64.1) 
 
14 (35.9) 
 
19 (48.7)  
 
20 (51.3) 
Maintained RCC - - 16 (41.0) 
Remained non-RCC - - 11 (28.2) 
Became RCC - - 3 (7.7) 
Became non-RCC - - 9 (23.1) 
McNemar comparison p   .146 
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In full remission 
Not in full remission 
9 (23.1) 
30 (76.9) 
11 (28.2) 
28 (71.8) 
Maintained full remission 0 (0) 0 (0) 7 (17.9) 
Remained BDD-YBOCS  > 12 30 (76.9) 28 (71.8) 26 (66.7) 
Became in remission 9 (23.1) 11 (28.2) 4 (10.3) 
Became symptomatic 0 (0) 0 (0) 2 (5.1) 
McNemar comparison p .004 .001 .687 
   
    
In partial remission 
Not in partial remission 
21 (53.8) 
18 (46.2) 
22 (56.4) 
17 (43.6) 
Maintained partial remission 0 (0) 0 (0) 18 (46.2) 
Remained BDD-YBOCS  ≥ 24 18 (46.2) 17 (43.6) 14 (35.9) 
Became in partial remission 21 (53.8) 22 (56.4) 4 (10.3) 
Became symptomatic 0 (0) 0 (0) 3 (7.7) 
McNemar comparison p <.001 <.001 1.00 
       
Relapsed 
Not relapsed 
 
 
 
5 (15.2) 
28 (84.8) 
Maintained relapse - - 0 (0) 
Remained in remission - - 17 (56.7) 
Became relapsed - - 4 (13.3) 
Became in remission - - 0 (0) 
McNemar comparison p - - .125 
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Table 5.  
Comparisons between participants at baseline who did or did not improve by a 30% BDD-YBOCS score decrease between baseline and long-
term follow-up. 
 
  Improved with 30% 
decrease in BDD-YBOCS 
score 
Did not improve (30% 
BDD-YBOCS 
Comparison 
  (n=18) (n=21) 
Referral, n (%) Local Primary Care 17 (94.4) 14 (66.7) 
Fisher’s exact test p = .049 
 Secondary or Tertiary Care 1 (5.6) 7 (33.3) 
Baseline measure, mean (SD) MADRS 23.67 (11.32) 31.43 (10.68) U = 113.50, Z = -2.13, p = .003, d = 0.73 
 BABS 18.83 (5.68) 17.90 (4.89) U = 157.00, Z = -.906, p = .373 
 PHQ-9 11.89 (7.31) 15.24 (5.36) U = 128.00, Z = -1.72, p = .087 
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Supplementary Table 6.  
Multiple regression of analysis of the participants who were followed up in the long term 
 
 
Long term follow up 
outcome variable 
Predictor variable B SE B β p R2 
BDD-YBOCS Constant -10.82 12.86 - .408 
.204  Baseline BDD-YBOCS .997 .389 .467 .016 
 Duration of follow-up -.071 .246 -.052 .776 
 
Note SE B = Standard error of B 
 
 
 
 
 
 
